The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing – Psychedelic Alpha
VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian
September 5, 2023